Antibiotic susceptibility and molecular characterization based on whole-genome sequencing of Staphylococcus aureus causing invasive infection in children and women living in Southw... by Li Liu, Ziyi Yan, Fumei He, Jie Chen, Linghan Kuang, Xingxin Liu, Yali Cui, Xia Wang, Chenglin Miao, Hong Li, Yongmei Jiang

“…Abstract Background Staphylococcus aureus is one of the most common pathogens that colonizes human skin/mucous membranes, where it causes local infection that can progress to invasive infection, resulting in high morbidity and mortality worldwide. …”
Get full text

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer by Riqing Huang, Anqi Hu, Qixiang Rong, Ditian Shu, Meiting Chen, Wei Yang, Yue Zhang, Qiufan Zheng, Xin An, Cong Xue, Haifeng Li, Yanxia Shi

“…Patients with amplifications in cell cycle-related genes showed inferior median progression-free survival (PFS) than those without amplifications (2.07 months vs. 8.40 months; HR = 5.24; 95% CI 2.11–13.01; p < 0.001), particularly in HER2-low patients (2.07 months vs. 8.27 months; HR = 4.23; 95% CI 1.50–11.91; p = 0.004). …”
Get full text

Artificial intelligence-based prediction of second stage duration in labor: a multicenter retrospective cohort analysisResearch in context by Xiaoqing Huang, Xiaodan Di, Suiwen Lin, Minrong Yao, Suijin Zheng, Shuyi Liu, Wayan Lau, Zhixin Ye, Zilian Wang, Bin Liu

“…While extending the duration of second stage can reduce primary cesarean delivery rates, it may increase maternal and neonatal morbidities as the duration progresses. We aimed to develop a personalized machine learning (ML) model to predict the possible second-stage duration. …”
Get full text

Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV Pancreatic Cancer: A Preliminary Study by Saskia Hussung, Maria E. Hess, Elham Bavafaye Haghighi, Uwe A. Wittel, Melanie Boerries, Ralph M. Fritsch

“…<i>KRAS</i>^mut cfDNA increase at the time of the first follow-up could predict inferior progression-free survival (PFS) (Hazard ratio (HR) = 3.40, <i>p</i> = 0.0003) and overall survival (OS) (HR = 4.91, <i>p</i> < 0.0001). …”
Get full text

Regulatory T Cell Phenotype Related to Cytokine Expression Patterns in Post‐COVID‐19 Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis by Sara Gangi, Laura Bergantini, Irene Paggi, Marco Spalletti, Paolo Cameli, Elena Bargagli, Miriana d'Alessandro

“…Conclusion A variety of immune cells is involved in the development and progression of pulmonary fibrosis confirming an immunological similarity between IPF and PCLF. …”
Get full text

SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI) by Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Roberto Scarsini, Luca Bergamaschi, Leonardo Portolan, Matteo Armillotta, Giuseppe Esposito, Elisabetta Moscarella, Giovanni Benfari, Claudio Montalto, Monika Shumkova, Elayne Kelen de Oliveira, Francesco Angeli, Mateusz Orzalkiewicz, Margherita Fabroni, Nurcan Baydaroglu, Andrea Raffaele Munafò, Daniele Oreste D’Atri, Matteo Casenghi, Lucia Scisciola, Michelangela Barbieri, Raffaele Marfella, Felice Gragnano, Edoardo Conte, Dario Pellegrini, Alfonso Ielasi, Daniele Andreini, Martin Penicka, Jacopo Andrea Oreglia, Paolo Calabrò, Antonio Bartorelli, Carmine Pizzi, Tullio Palmerini, Marc Vanderheyden, Francesco Saia, Flavio Ribichini, Emanuele Barbato

“…Patients not treated with SGLT2i were more likely to progress to a worse EVCD stage over time (p = 0.018). …”
Get full text

Subjective cognitive decline predicts longitudinal neuropsychological test performance in an unsupervised online setting in the Brain Health Registry by Jae Myeong Kang, Manchumad Manjavong, Chengshi Jin, Adam Diaz, Miriam T. Ashford, Joseph Eichenbaum, Emily Thorp, Elizabeth Wragg, Kenton H. Zavitz, Francesca Cormack, Anna Aaronson, R. Scott Mackin, Rachana Tank, Bernard Landavazo, Erika Cavallone, Diana Truran, Sarah Tomaszewski Farias, Michael W. Weiner, Rachel L. Nosheny

“…Additionally we assessed the ability of ECog to identify ‘decliners’, who exhibited the worst PAL progression slopes corresponding to the fifth percentile and below. …”
Get full text

Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan by Jeffrey M. Hord, Sarah Burns, Tobias Willer, Matthew M. Goddeeris, David Venzke, Kevin P. Campbell

“…Methods To evaluate how the loss of O-mannosylated DG in skeletal muscle affects the development and progression of myopathology, we generated and characterized mice in which the Pomt1 gene was specifically deleted in skeletal muscle (Pomt1skm) to interfere with POMT1/2 enzyme activity. …”
Get full text

Computational analysis of heat transfer and fluid flow characteristics in a diamond microchannel heat sink with orthogonal ribs by Liang Du, Wenbo Hu, Ningkang Deng, Zhaoyang Zhang, Hongxing Wang

“…Following that, the reverse triangular orthogonal rib microchannel heat sink, forward triangular orthogonal rib microchannel heat sink, and rhombic orthogonal rib microchannel heat sink demonstrated progressively lower comprehensive performance, with the circular orthogonal rib microchannel heat sink exhibiting the lowest comprehensive performance. …”
Get full text

Evaluating choroidal vascular changes in young adults with high myopia utilizing swept source optical coherence tomography angiography by Qing wang, Lin-Bo He, Sha Li, Hong-Ling Liu, Yong Liu

“…This also indicates that the subfoveal and parafoveal temporal CSHL densities are crucial for monitoring changes during myopia progression. Additionally, there appears to be a compensatory mechanism for high myopia to sustain visual function.…”
Get full text

Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis by Marcello Dallio, Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Giorgia Iadanza, Simone Olivieri, Annachiara Coppola, Marco Niosi, Alessandro Federico

“…Results The prevalence of dysgeusia increased with the liver disease progression, appearing significantly higher in ACLD compared with ≤ F3 (65.7% vs 5%, p:0.003), as well as in dACLD compared to cACLD patients (58.5 vs 7.1% p < 0.0001). …”
Get full text

The expression landscape and clinical significance of methyltransferase-like 17 in human cancer and hepatocellular carcinoma: a pan-cancer analysis using multiple databases by Yezhou Ding, Mingyang Feng, Wanqing Chi, Xiaoyin Wang, Baoyan An, Kehui Liu, Shike Lou, Xiaolin Wang, Hui Wang

“…Abstract Background Methyltransferase-like (METTL) family protein plays a crucial role in the progression of malignancies. However, the function of METTL17 across pan-cancers, especially in hepatocellular carcinoma (HCC) is still poorly understood. …”
Get full text

TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial by Wei Gao, Ping Hu, Aung Naing, Meredith McKean, Anthony Tolcher, Lillian L Siu, Keyvan Tadjalli-Mehr, Anja Victor, Emilia Richter, Marco A F Nogueira Filho, Thomas Kitzing, Stephan Gleicher, Daniel Holland

“…Overall, median overall survival and progression-free survival were 7.6 (95% CI 4.9, 12.0) and 1.4 (95% CI 1.3, 1.8) months, respectively. …”
Get full text

Climate change risks illustrated by the Intergovernmental Panel on Climate Change (IPCC) “burning embers” by P. Marbaix, P. Marbaix, P. Marbaix, A. K. Magnan, A. K. Magnan, A. K. Magnan, V. Muccione, V. Muccione, P. W. Thorne, Z. Zommers

“…While initially designed to illustrate five overarching Reasons for Concern, these diagrams have been progressively applied to risks in specific systems and regions over the last 10 years. …”
Get full text

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2... by Nobuaki Matsubara, Hideaki Miyake, Hiroji Uemura, Atsushi Mizokami, Hiroaki Kikukawa, Takeo Kosaka, Kazuo Nishimura, Motonobu Nakamura, Kazuki Kobayashi, Atsushi Komaru, Yuko Mori, Shigeyuki Toyoizumi, Natsuki Hori, Yoshiko Umeyama, Hirotsugu Uemura

“…ABSTRACT Background In TALAPRO‐2, the poly(ADP‐ribose) polymerase inhibitor talazoparib plus the androgen receptor–signaling inhibitor enzalutamide improved radiographic progression‐free survival (rPFS) versus placebo plus enzalutamide (hazard ratio [HR] = 0.63; 95% CI, 0.51–0.78) in molecularly unselected patients with metastatic castration‐resistant prostate cancer (mCRPC). …”
Get full text

Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter co... by Yoshihiko Tasaki, Shuzo Hamamoto, Shimpei Yamashita, Junya Furukawa, Kazutoshi Fujita, Ryotaro Tomida, Makito Miyake, Noriyuki Ito, Hideto Iwamoto, Yoshihisa Mimura, Yosuke Sugiyama, Rei Unno, Atsushi Okada, Takahiro Yasui, Yoko Furukawa-Hibi

“…Multivariate analysis showed that an eosinophil of ≥3.0% was a risk factor for severe irAEs (odds ratio, 6.01). Median progression-free survival (mPFS), mPFS from the start of ipilimumab plus nivolumab therapy to second-line therapy (mPFS2), and median overall survival (mOS) were the shortest in the non-irAE group. …”
Get full text

Relationship Between Short‐Term Outcomes and PD‐L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated W... by Akihiro Ohara, Taisuke Mori, Mai Itoyama, Kazuki Yokoyama, Shun Yamamoto, Ken Kato, Yoshitaka Honma

“…Conversely, nivolumab is utilized for platinum‐pretreated R/M‐HNSCC regardless of the positive tumor proportion score (TPS) following the results of the CheckMate‐141; however, its subgroup analysis indicated that TPS‐positive population tended to have a relatively high overall response rate and progression‐free survival (PFS). Although, the superior PD‐L1 evaluation method for predicting APA therapy efficacy in R/M‐HNSCC and the appropriate cut‐off value remain undetermined. …”
Get full text

Retinoblastoma. Part 2.&nbsp; Treatment strategies for intraocular retinoblastoma by S.V. Ivanova, S.A. Kuleva, N.N. Sadovnikova, M.I. Komissarov, M.N. Chistyakova, A.V. Khokhlova, N.A. Shchegoleva

“…The volume of adjuvant therapy is based on the histological risk factors for disease progression. This paper discusses the algorithms to determine risk factors and further systemic treatment strategy in several large study groups. …”
Get full text

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma by Dirk Hose, Seemun Ray, Sina Rößler, Ulrich Thormann, Reinhard Schnettler, Kim de Veirman, Thaqif El Khassawna, Christian Heiss, Anne Hild, Daniel Zahner, Francisca Alagboso, Anja Henss, Susanne Beck, Martina Emde-Rajaratnam, Jürgen Burhenne, Juliane Bamberger, Eline Menu, Elke de Bruyne, Michael Gelinsky, Marian Kampschulte, Marcus Rohnke, Sabine Wenisch, Karin Vanderkerken, Thomas Hanke, Anja Seckinger, Volker Alt

“…Myeloma cells surviving treatment in the presumably protective environment of bone lesions impede their healing by continued impact on bone turnover and can explain regular progression of patients without detectable minimal residual disease (MRD). …”
Get full text

Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma by Jeannette C. Oosterwijk-Wakka, Liesbeth Houkes, Loes F.M. van der Zanden, Lambertus A.L.M. Kiemeney, Kerstin Junker, Anne Y Warren, Tim Eisen, Ulrich Jaehde, Marius T Radu, Rob Ruijtenbeek, Egbert Oosterwijk

“…Introduction: Treatment with Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor (TKI) has increased the progression-free survival (PFS) and overall-survival (OS) of patients with metastasized renal cell carcinoma (mRCC). …”
Get full text